How cell particles affect blood stem cells in myelofibrosis
Part of Blood & lymphatic clinical trials.
This trial is looking at whether tiny particles released by certain cells from people with myelofibrosis can affect their blood-forming stem cells. The goal is to understand the disease better and find new treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary myelofibrosis (PMF).
- You have a specific genetic mutation called JAK2 V617F+.
- You are not currently receiving treatment for myelofibrosis.
- You are at least 18 years old.
- You have not had your spleen removed.
- You have not had a bone marrow transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests giving a JAK inhibitor before and after a reduced-intensity stem cell transplant to treat primary or secondary myelofibrosis. The goal is to improve disease control while using a less harsh transplant approach.
This study tests a new drug called LY5830966 for people with myelofibrosis whose disease has not responded to or has returned after treatment with a type I JAK2 inhibitor. The drug aims to help reduce symptoms and improve outcomes.
This study tests a new way to detect scar tissue in the bone marrow using a special scan and blood test. It might help doctors see how your disease is changing without needing a bone marrow biopsy.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial studies whether an allogeneic (donor) stem cell transplant can help people with higher-risk myelofibrosis (fibrosis in the bone marrow). It looks at outcomes in different donor types as determined by matching rules and patient risk level.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.